 "Jubilant Life gains on USFDA nod for generic anti-asthma tablets")
Jubilant Life Sciences has soared 6% to Rs 169 on BSE after the pharmaceutical company said it has received final approval from the US Food and Drug Administration (US FDA) for generic Montelukast Sodium chewable tablets used in the treatment of asthma and to relieve symptoms of seasonal allergies.
The total market size for Montelukast tablets as per IMS is $83 Million per annum, Jubilant Life Sciences said in a statement.
As on December 31, 2014, Jubilant Life Sciences had a total of 781 filings for formulations of which 333 have been approved in various regions globally. This includes 72 abbreviated new drug application (ANDAs) filed in the US, of which 35 have been approved and 46 Dossier filings in Europe. So far, we have received 10 ANDA approvals during FY 2015, it added.
The stock opened at Rs 168 and touched a high of Rs 175 on BSE. A combined about one million shares changed hands on the counter till 1002 hours on BSE and NSE.
The total market size for Montelukast tablets as per IMS is $83 Million per annum, Jubilant Life Sciences said in a statement.
As on December 31, 2014, Jubilant Life Sciences had a total of 781 filings for formulations of which 333 have been approved in various regions globally. This includes 72 abbreviated new drug application (ANDAs) filed in the US, of which 35 have been approved and 46 Dossier filings in Europe. So far, we have received 10 ANDA approvals during FY 2015, it added.
The stock opened at Rs 168 and touched a high of Rs 175 on BSE. A combined about one million shares changed hands on the counter till 1002 hours on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%